FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

CRYSTAL ROGER

2. Date of Event Requiring Statement (MM/DD/YYYY)
12/10/2014 

3. Issuer Name and Ticker or Trading Symbol

Lightlake Therapeutics Inc. [LLTP]

(Last)        (First)        (Middle)

445 PARK AVENUE, 9TH FLOOR

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                            ___ X ___ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Chief Executive Officer /

(Street)

NEW YORK, NY 10022       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock par value $0.001   (1) 5000   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option   12/31/2012   12/30/2022   Common Stock   25000   $12.00   D    
Option   12/31/2012   (2) 12/30/2017   Common Stock   85000   $15.00   D    
Warrant   12/31/2012   (2) 12/30/2017   Common Stock   40000   $15.00   D    
Option   12/31/2013   12/30/2023   Common Stock   75000   $6.00   D    
Option   5/1/2013   (3) 12/30/2023   Common Stock   200000   $8.00   D    
Option   5/1/2013   (4) 12/30/2023   Common Stock   175000   $10.00   D    
Option   8/1/2013   7/31/2023   Common Stock   50000   $15.00   D    
Option   8/1/2013   7/31/2023   Common Stock   50000   $20.00   D    
Option   6/15/2014   (5) 6/14/2024   Common Stock   150000   $5.00   D    
Option   6/15/2014   (5) 6/14/2024   Common Stock   200000   $8.00   D    
Option   10/27/2015   (6) 10/26/2025   Common Stock   500000   $7.25   D    

Explanation of Responses:
( 1)  This Form 3 is a late filing reporting the beneficial ownership of the Reporting Person as of 12/10/2014, the effective date of the Issuer's Form 8-A registration statement which registered the common stock of the Issuer for the first time under Section 12 of the Exchange Act. In December 2014, the Issuer effected a one-for-one hundred reverse stock split of its common stock (the "1:100 Reverse Stock Split"). Unless otherwise noted, all share amounts and exercise prices listed in this Form 3 been retroactively adjusted for the 1:100 Reverse Stock Split as if such stock splits occurred prior to the issuance of such shares, warrants, or options.
( 2)  These options and this warrant may only be exercised between the following dates: (i) the date on which the Company's price per share has traded at or above US$0.30 (set prior to the 1:100 Reverse Stock Split) for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) five years from the grant date.
( 3)  50,000 vested on 5/1/2013, 50,000 vested on 11/1/2013, and 100,000 vested on 12/31/2013. All expire 10 years after their respective vesting dates.
( 4)  25,000 vested on 5/1/2013, 25,000 vested on 8/1/2013; 25,000 vested on 11/1/13, and 100,000 vested on 12/31/13. All expire 10 years after their respective vesting dates.
( 5)  These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of the next trial with respect to the opioid overdose reversal treatment; (B) the entrance into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment; or (C) the filing of a New Drug Application with the U.S. Food and Drug Administration with respect to the opioid overdose reversal treatment; and (ii) the Expiration Date.
( 6)  These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
CRYSTAL ROGER
445 PARK AVENUE, 9TH FLOOR
NEW YORK, NY 10022 		X X Chief Executive Officer

Signatures
/s/ Dr. Roger Crystal 10/29/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Opiant Pharmaceuticals Charts.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Opiant Pharmaceuticals Charts.